Categories Earnings, Health Care

Portola’s stock crashes 12% despite Q1 results beat

Shares of Portola Pharmaceuticals (NASDAQ: PTLA) plummeted 12.7% in morning trade on Wednesday despite the company achieving better-than-expected revenue and earnings for the first quarter of 2019.

Total revenues grew to $22.2 million during the first quarter of 2019 from $6.6 million in the prior-year period. Net product revenues from Andexxa sales totaled $20.3 million while revenue from Bevyxxa sales amounted to $77,000. Collaboration and license revenues were $1.8 million.

On a GAAP basis, net loss attributable to Portola was $78.2 million, or $1.17 per share, compared to $84.2 million, or $1.28 per share, last year. This year’s quarterly results include the effect of two charges related to the US FDA’s approval of the company’s Gen 2 manufacturing process. Adjusted net loss was $68.4 million, or $1.02 per share.

R&D expenses decreased to $35.6 million from $60.1 million in the year-ago quarter, mainly due to the manufacturing costs for Andexxa Gen 2 being capitalized and no longer flowing through R&D.

Portola stated that the full commercial launch of Andexxa in the US is off to a great start and the quarterly results reflected strong demand for the product. The company achieved another long-term growth catalyst with the approval of Ondexxya in Europe.

Portola is making progress with cerdulatinib and the company anticipates defining its safety and efficacy profile through a number of scientific presentations in the second quarter.

Portola’s shares have rallied 79% year to date.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Infographic: How DICK’S Sporting Goods (DKS) performed in Q3 2024

DICK'S Sporting Goods, Inc. (NYSE: DKS) reported its third quarter 2024 earnings results today. Net sales remained relatively unchanged at $3 billion compared to the same period a year ago. Comparable

Infographic: Kohl’s Corporation (KSS) reports lower Q3 sales and profit

Kohl’s Corporation (NYSE: KSS) Tuesday announced financial results for the third quarter of 2024, reporting a year-over-year decline in sales and net income. The company also provided guidance for fiscal

Key metrics from Best Buy Co.’s (BBY) Q3 2025 earnings results

Best Buy Co., Inc. (NYSE: BBY) reported its third quarter 2025 earnings results today. Enterprise revenues decreased to $9.4 billion from $9.7 billion reported in the same period a year

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top